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Abstract Cost-effectiveness analysis as a means to
evaluate medical innovations has become well accepted in
the UK and several other Western countries. An important
assumption underlying this method is that costs and effects
are constant over time. In reality, however, and especially
in the short run, variations in costs and effects are likely to
occur. These variations can lead to considerable deviations
from the outcome of a conventional economic evaluation,
which in turn may lead to serious implementation problems
at a local level. Taking time into account explicitly in
economic evaluations in health care may enhance their
utility for both societal and local decision making, and may
ultimately smooth the adoption of new and basically cost-
effective health care technologies.
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Introduction
Cost-effectivenessanalysis(CEA)aspartoftheevaluationof
medical innovationshas become well acceptedand isapplied
widely in several European countries. For example, in the
UK,theNationalInstituteofClinicalExcellence(NICE)uses
cost-effectiveness outcomes, expressed as cost per quality
adjusted life year gained, as a criterion for coverage
recommendations to the National Health Service. In the
Netherlands, the Dutch HealthInsurance Board (CVZ) usesa
cost-effectiveness criterion in their advice to the minister on
adding new technologies to the beneﬁt package. In line with
this development, research into CEA methodology has
playedamajorroleintheﬁeldofhealtheconomicsinthepast
decades,focusingonawiderangeofissues,suchasqualityof
life measurement and value of information research. Most of
this research has been aimed directly or indirectly at
improving the validity of cost-effectiveness outcomes. This
large attention on economic evaluation in health care has
given us a method—the CEA—that is relatively well
researched and provides a generally trusted estimate of the
cost-effectiveness of a medical innovation. However, CEA is
based on several assumptions. One important assumption is
thatcostsandeffectsareconstantovertime(i.e.,thattherates
at which costs are incurred and health outcomes are obtained
will not vary during the lifetimes of the competing technol-
ogies). In reality, however, and especially in the short run,
variations in costs and effects might occur, for example due
to learning effects and suboptimal occupancy rates of ﬁxed
factors of production. Here, we show that, in the short run,
costs-effectiveness may deviate considerably from the out-
come of a conventional economic evaluation, and we will
discuss the implicationsofsuchdeviations.Buildingonthese
observations, we argue that taking time into account in eco-
nomic evaluations (1) will make cost-effectiveness outcomes
more realistic, and (2) could mean a step forward in bridging
the gap between societal and local decision making, thereby
makingcost-effectivenessoutcomesmore usefulfor all kinds
of decision makers.
The role of time in cost-effectiveness analysis
Standard CEA is conducted from a societal perspective and
includes a cost and beneﬁt assessment for society in
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DOI 10.1007/s10198-011-0374-3general. In practice, standard CEA starts by collecting all
the relevant costs and effects for a health care technology
over a relevant time period, and subsequently averages
these total cost and effects over this period. Next, differ-
ential costs and effects are calculated as the difference in
average costs and effects between alternative technologies.
These differential costs and effects are combined into an
incremental cost-effectiveness ratio (ICER), or an incre-
mental net monetary beneﬁt (INMB). The ICER represents
the ratio of differential costs to differential effects, and the
INMB is acquired by multiplying the cost-effectiveness
threshold by the differential effects and then subtracting the
differential costs [1]. In utilizing the ICER or the INMB,
differences in costs and effects between alternative medical
innovations are considered to be constant over these
innovations’ respective lifetimes. This means that, fol-
lowing implementation of an innovation, possible efﬁ-
ciency gains are assumed to accumulate at a constant rate,
as found in the preceding trial or modeling study. Thus,
average costs and effects found in the trial period are
assumed to be representative of the average costs and
effects over the technology’s lifetime. Therefore, standard
CEA focuses inherently on the long-run consequences of
adopting a technology. In the long run, technology’s costs
and effects can indeed be expected to reach or approximate
a steady state, so from a long-run perspective, the modus
operandi of the standard CEA seems very justiﬁable.
However, in reality, a technological switch will usually
give rise to a phase where the average costs and effects
(and consequently the cost-effectiveness) vary and have
not yet reached a steady state. Therefore, although using
constant ICERs and INMBs may be convenient, the
assumption of constant marginal cost-effectiveness out-
comes is an idealization and is not very realistic as it
neglects the short run, where the old and new technology
often co-exist. However, the question is how much of a
problem this is in practice: to what extent does the
marginal cost-effectiveness of the technologies that are
being compared vary over time, and how well does the
presumed steady state situation approximate the actual
time-dependent path?
Short-run vs long-run cost-effectiveness
The CEA framework considers costs, effects and hence
cost-effectiveness outcomes as unchanging quantities in
some steady state. However, this steady state is achieved
only when all trace of the previous technology has disap-
peared, in other words, when (1) the new technology is
fully functional, (2) staff have mastered the new technol-
ogy, (3) a more or less constant occupancy rate for the new
technology has been achieved, (4) all costs for the old
technology have dissipated, and (5) there is no longer any
spillover of effects from the old technology into the new
situation. As noted above, in the initial time period after
introduction of a new technology, these conditions are not
met. During this time period costs may be induced for both
technologies, and clinical effectiveness for the new tech-
nology is likely to be not yet optimal [2]. This may very
well result in a negative deviation from the long-run cost-
effectiveness outcome during the short-run. This is illus-
trated in Fig. 1, which depicts time-dependent paths for the
average costs and effects of both health technologies and
for the resulting ICER. It can be seen that the ICER is
indeed less favorable in the short run as compared to the
long-run steady state.
A multitude of reasons could contribute to these devia-
tions,suchaslearningeffects,rigidlaborcontracts,effectsof
the old technology spilling over into the new technology’s
period, ﬁxed production factors for the old technology that
may become a deadweight, a temporary coexistence of the
two technologies leading to diseconomies of scale (for
instance, due to a gradual implementation of the new
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Fig. 1 Average costs (a) and
effects (b) for the new and the
old technology over time, and
the resulting incremental cost-
effectiveness ratio (ICER) (c)a s
a function of time
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123technology combined with a gradual dismantling of the old
technology’s infrastructure), budget restrictions within the
relevant planning period, etc. [3–5]. Hence, it seems that
short-run deviations from the long-run oriented cost-effec-
tiveness model could indeed be substantial. This will be the
case especially if the short run is a substantial part of a
technology’s economiclifetime. Economic theory generally
states that the short run becomes irrelevant if the long run is
sufﬁcientlylong.However,giventheturbulencewithrespect
totechnologicalchangethatcanbeseenincertainhealthcare
areas, we expect that the short run might be relevant for a
relatively large number of innovations. Of course, the mag-
nitude and importance of these deviations in a particular
CEAdependonthespeciﬁcsofthetechnologiesandsettings
underconsideration.Here,ithelpsthatthenatureandimpact
of these factors might to some extent be predictable and
systematic. For example, short-run cost-effectiveness out-
comes for surgical procedures that require a lot of time to
master will display a large deviation from long-run out-
comes, due to the longer duration of surgery and higher
number of complications in the short run. On the other hand,
a substitution of one drug for another will probably bring
about relatively small short-run deviations, as it seems hard
to see which of the above-mentioned reasons would con-
tribute substantially in this case, except possibly learning
effects due to initial dosing difﬁculties.
A good example with which to illustrate the occurrence
of short-run deviations when introducing a new technology
is the conversion from analog screen ﬁlm mammography
(SFM) to digital mammography (FFDM) in the Dutch
population-based breast cancer screening program. Here, a
preliminary study was performed to assess the feasibility of
converting to a ﬁlmless digital screening program [6]. In
this study, annual savings associated with abandoning the
old SFM technology were estimated at €13,270,000, and
the annual extra cost of adopting the new FFDM technol-
ogy were estimated at €12,285,000. Hence, the Dutch
government concluded that substituting SFM for FFDM
would yield net annual savings of €985,000. Although
estimations suggested that the transition phase would last
3 years, the anticipated net annual savings were assumed to
be realized immediately. This assumption is applied con-
sistently in standard CEA, even in projects where a sig-
niﬁcant change in infrastructure necessitates a long phase-
in process, implying coexistence of two technologies,
potentially leading to diseconomies of scale. As several
exogenous factors (e.g. European tender rules) delayed the
adoption and stretched the transition process, potentially
obsolete SFM equipment did not immediately become a
deadweight. However, due to the extension of the transition
process, short-run losses associated with the coexistence of
SFM and FFDM are likely to have caused serious inefﬁ-
ciencies during the transition phase.
In order to actually develop a time-dependent cost-
effectiveness model and quantify short-run deviations from
the steady state, the approach outlined here will have to be
speciﬁed further and quantiﬁed through mathematical
modeling. In a preliminary paper [2], a three-step model
has been developed that operates by ﬁrst determining the
initial efﬁciency losses inﬂicted by deadweight ﬁxed pro-
duction factors for the old technology, then adjusting for
reﬁlling and writing off freed capacity over time, and
ﬁnally calculating the length of the short-run time frame in
which the efﬁciency losses exist. This model was applied to
two cases: substituting in-hospital dialysis for continuous
ambulatory peritoneal dialysis, and digitizing a radiogra-
phy department. In the dialysis case, it was shown that the
short-run INMB decreased by 8.6% compared to the steady
state INMB. The radiography case illustrated that short-run
deviations can indeed be very substantial, as incorporating
these deviations changed the cost-effectiveness outcome
from favorable to unfavorable [2]. The model mentioned
above could be extended further by allowing for delayed
adoption of the new technology, thereby making it possible
to calculate short-run efﬁciency losses for a technology that
is implemented gradually. Such a model would operate by
taking into account the rate of implementation of the new
technology and depreciation of capital of the old technol-
ogy in order to integrate the NMB functions for both the
old as well as the new technology into one time-dependent
INMB function. One could also think of incorporating
learning effects into a model, reasoning that learning leads
to an overestimation of costs and an underestimation of
effectiveness during the trial period and that these devia-
tions from steady state cost-effectiveness outcomes can be
modeled as a function of clinical trial length. Although
time has not been much of an issue in economic evaluation
in health care up to now, we consider it possible and
important to develop models that are able to incorporate,
and thereby make visible, short-run deviations from the
steady state.
Consequences for local decision making
Besides making societal CEA more valid, another reason
why incorporating time in CEA could be relevant, is to
bridge the gap between societal and local decision making.
As mentioned above, CEA is a method used to assist
decision making when adding health technologies to ben-
eﬁt packages. In doing so, CEA adheres to a societal per-
spective. However, the consequences of decision making at
the societal level are felt at different levels in the health
care system. The societal decision to add a new technology
to the beneﬁt package might put pressure on local health
care providers, such as medical doctors, hospital managers,
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123prescribing advisors, hospital pharmacists and directors in
public health, to supply the new technology instanta-
neously. However, if short-run consequences on costs and
effects are not communicated to such providers, unantici-
pated losses might lead to second thoughts about
implementation of what is, in essence, a cost-effective
innovation, even potentially denying patients access to
more efﬁcient health care. Failing to acknowledge short-
run aspects in CEA may raise doubts about the validity of
its outcome, and may also lead to disappointment with
economic evaluations in general, as evidence on cost-
effectiveness is of less interest to decision makers who are
focusing on the short run [7]. Indeed, a prominent argu-
ment used by health care decision makers to resist the use
of CEA is the disconnect between formal CEAs, which
have a societal perspective and long-run orientation, and
the short-run perspective on decisions within health care
organizations [7–9]. Due to ever increasing budget pres-
sures, local decision makers are forced to focus on short-
run results. This is conﬁrmed by studies such as that of
Drummond et al. [10–12], which revealed that, in the UK,
30% of local decision makers state that being unable to
take a long-run view, due to the importance of their annual
budget, is an important obstacle to the use of economic
evaluations. Also, a recent small study aimed to determine
if ﬁnancial managers in the Dutch health care system focus
on short- or long-run efﬁciency showed similar results
(Radboud University Nijmegen Medical Center, van de
Wetering et al., manuscript in preparation). Therefore, it
seems that the real problem articulated by local decision
makers is that, given their short-run orientation, CEAs are
seen as insufﬁciently valid for their organization. Incor-
porating short-run deviations in the cost-effectiveness
model might therefore improve trust in the validity and,
consequently, the usability of the ICER.
Conclusions
Taking into account the short run by explicitly modeling
time in CEA could lead to more accurate and realistic
estimates of the cost-effectiveness of medical innovations.
This would at least entail making a distinction between the
short and the long run. When short-run deviations from
standard CEA occur, they are often unanticipated and could
very well slow down the adoption of new and basically
cost-effective health care technologies. To enhance trust in
CEA, it is important to gain insight into the major factors
potentially contributing to short-run efﬁciency losses. All
in all, having a framework for CEA that incorporates time
and quantiﬁes short-run deviations could help prevent
unpleasant surprises, and provide an implementation
decision process with more valid cost-effectiveness data. In
the Netherlands, the importance of potential short-run
deviations in CEA has now been recognized and has indeed
been added to the new version of the Dutch manual for
costing research in health care [13].
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